Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET
Company Participants
Louise Wilkie - Investor Relations
Sandy Macrae - Chief Executive Officer
Rob Schott - Head of Development
Jason Fontenot - Chief Scientific Officer
Prathyusha Duraibabu - Chief Financial Officer
Bettina Cockroft - Chief Medical Officer
Conference Call Participants
Yanan Zhu - Wells Fargo
Nicole Germino - Truist Securities
Luca Issi - RBC Capital
Kelly O'Brien - Stifel
Gregory Harrison - Bank of America
Kevin Estok - Jefferies
Ritu Baral - Cowen
Patrick Trucchio - HC Wainwright
Operator
Thank you for standing by, and welcome to Sangamo First Quarter 2022 Teleconference Call. [Operator Instructions] Please be advised that today's conference is being recorded. [Operator Instructions] I would now like to hand the conference over to your speaker today, Ms. Louise Wilkie. Thank you. Please go ahead.
Louise Wilkie
Good afternoon, and thank you for joining us today. With me on the call this afternoon are Sandy Macrae, Chief Executive Officer; Mark McClung, Chief Operating Officer; Prathyusha Duraibabu, Chief Financial Officer; Jason Fontenot, Chief Scientific Officer; Rob Schott, Head of Development; and Bettina Cockroft, Chief Medical Officer. Slides from our corporate presentation can be found at our website, sangamo.com, under the Investors and Media section of the Events and Presentations page.
This call includes forward-looking statements regarding Sangamo's current expectations. These statements include, but are not limited to, statements related to the therapeutic and commercial potential of our product candidates. The anticipated plans and time lines of Sangamo and our collaborators for initiating and conducting clinical trials and presenting clinical data, execution of our corporate strategy, advancement of our product candidates, our 2022 financial guidance and other statements that are not historical facts. Actual results may differ materially from what we discuss today. These statements are subject to certain risks and uncertainties that are discussed in our filings with the SEC, specifically on our quarterly report on Form 10-Q for the fiscal quarter ended March 31, 2022, and our annual report on Form 10-K for the fiscal year ended December 31, 2021. The forward-looking statements stated today are made as of this date, and we undertake no duty to update such information, except as required by law. On this call, we discuss our non-GAAP operating expenses. Reconciliation of this measure to our GAAP operating expenses can be found in today's press release, which is available on our website.